Cuckos Pharmaceutical Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 29-07-2024
- Paid Up Capital ₹ 0.10 M
as on 29-07-2024
- Company Age 7 years 6 months
- Last Filing with ROC 31 Mar 2023
- Revenue 104.51%
FY 2023
- Profit 11.69%
FY 2023
- Ebitda 13.53%
FY 2023
- Net Worth 94.50%
FY 2023
- Total Assets 49.84%
FY 2023
About Cuckos Pharmaceutical
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per the Ministry of Corporate Affairs (MCA) records.
Neelam, Vishal Ohlan, Keshav Deo, and One other member serve as directors at the Company.
- CIN/LLPIN
U33309DL2017PTC314006
- Company No.
314006
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Mar 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cuckos Pharmaceutical Private Limited offer?
Cuckos Pharmaceutical Private Limited offers a wide range of products and services, including Animal Medicines & Health Care, Veterinary Medicines, Bird Food, Poultry & Animal Food, Animal Feed Supplement, Veterinary Injections.
Who are the key members and board of directors at Cuckos Pharmaceutical?
Executive Team (1)
N
Neelam
Managing DirectorAppointment Date: 06-Mar-2017
Status: Current
Board Members(3)
Financial Performance and Corporate Structure Insights of Cuckos Pharmaceutical.
Cuckos Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 104.51% increase. The company also saw a substantial improvement in profitability, with a 11.69% increase in profit. The company's net worth Soared by an impressive increase of 94.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cuckos Pharmaceutical?
In 2023, Cuckos Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
1 year 4 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cuckos Pharmaceutical?
Cuckos Pharmaceutical has a workforce of 1 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cuckos Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cuckos Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
